Epizyme, Inc.

NasdaqGS:EPZM Rapporto sulle azioni

Cap. di mercato: US$247.5m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Epizyme Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Grant Bogle

Amministratore delegato

US$3.0m

Compenso totale

Percentuale dello stipendio del CEO9.9%
Mandato del CEOless than a year
Proprietà del CEOn/a
Durata media del management2.3yrs
Durata media del Consiglio di amministrazione10.2yrs

Aggiornamenti recenti sulla gestione

Recent updates

Epizyme GAAP EPS of -$0.21, revenue of $27.5M

Aug 09

Epizyme Acquisition By Ipsen: CVR Value

Jul 05

Some Epizyme, Inc. (NASDAQ:EPZM) Analysts Just Made A Major Cut To Next Year's Estimates

May 16
Some Epizyme, Inc. (NASDAQ:EPZM) Analysts Just Made A Major Cut To Next Year's Estimates

Epizyme: Taking Advantage Of Recent Sell-Off

Nov 25

Health Check: How Prudently Does Epizyme (NASDAQ:EPZM) Use Debt?

Sep 14
Health Check: How Prudently Does Epizyme (NASDAQ:EPZM) Use Debt?

Industry Analysts Just Made A Sizeable Upgrade To Their Epizyme, Inc. (NASDAQ:EPZM) Revenue Forecasts

Aug 10
Industry Analysts Just Made A Sizeable Upgrade To Their Epizyme, Inc. (NASDAQ:EPZM) Revenue Forecasts

Epizyme: Potential Comeback With Tazemetostat After Initial Sales Challenge

Jun 22

Is Epizyme (NASDAQ:EPZM) Using Too Much Debt?

Jun 08
Is Epizyme (NASDAQ:EPZM) Using Too Much Debt?

Epizyme gains as peer Constellation attracts sizable premium from MorphoSys

Jun 02

Epizyme, Inc. 2021 Q1 - Results - Earnings Call Presentation

May 07

Epizyme, Inc. (NASDAQ:EPZM) Analysts Just Trimmed Their Revenue Forecasts By 41%

Feb 25
Epizyme, Inc. (NASDAQ:EPZM) Analysts Just Trimmed Their Revenue Forecasts By 41%

Is Epizyme (NASDAQ:EPZM) Using Too Much Debt?

Jan 16
Is Epizyme (NASDAQ:EPZM) Using Too Much Debt?

Epizyme says Boehringer terminates collaboration agreement

Dec 24

Would Shareholders Who Purchased Epizyme's (NASDAQ:EPZM) Stock Year Be Happy With The Share price Today?

Dec 12
Would Shareholders Who Purchased Epizyme's (NASDAQ:EPZM) Stock Year Be Happy With The Share price Today?

Epizyme Q3 2020 Earnings Preview

Nov 05

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Grant Bogle rispetto agli utili di Epizyme?
DataCompenso totaleStipendioGuadagni aziendali
Jun 30 2022n/an/a

-US$208m

Mar 31 2022n/an/a

-US$236m

Dec 31 2021US$3mUS$299k

-US$251m

Sep 30 2021n/an/a

-US$267m

Jun 30 2021n/an/a

-US$257m

Mar 31 2021n/an/a

-US$251m

Dec 31 2020US$196kn/a

-US$232m

Sep 30 2020n/an/a

-US$222m

Jun 30 2020n/an/a

-US$202m

Mar 31 2020n/an/a

-US$192m

Dec 31 2019US$309kn/a

-US$173m

Compensazione vs Mercato: Grant's total compensation ($USD3.01M) is above average for companies of similar size in the US market ($USD1.66M).

Compensazione vs guadagni: Grant's compensation has increased whilst the company is unprofitable.

AMMINISTRATORE DELEGATO

Grant Bogle (64 yo)

less than a year

Mandato

US$3,011,807

Compensazione

Mr. Grant C. Bogle has been Chief Executive Officer, President and Director at Epizyme, Inc. since August 9, 2021 and serves as Principal Financial Officer since November 1, 2021 and served as its Independ...

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Grant Bogle
Presidentless than a yearUS$3.01mNessun dato
Jeffery Kutok
Chief Scientific Officer2.3yrsUS$2.86m0.0080%
$ 19.9k
H. Horvitz
Co-Founder & Chairman of the Scientific Advisory Boardno dataNessun datoNessun dato
Yi Zhang
Scientific Co-Founder & Member of The Scientific Advisory Boardno dataNessun datoNessun dato
Jerald Korn
Chief Operating Officerless than a yearNessun datoNessun dato
Joseph Beaulieu
Senior VP4.1yrsNessun dato0.0058%
$ 14.3k
Craig West
Vice President of Investor Relationsno dataNessun datoNessun dato
John Weidenbruch
Senior VPno dataNessun datoNessun dato
Tanja Weber
Chief Business Officer3.6yrsNessun datoNessun dato
Mark De Rosch
Chief Regulatory Officer2.8yrsNessun datoNessun dato
Rebecca Mehrwerth
Senior VP & Head of Commercialless than a yearNessun datoNessun dato
Christoph Diefenbach
Laboratory Manager of Research & Developmentno dataNessun datoNessun dato

2.3yrs

Durata media

56.5yo

Età media

Gestione esperta: EPZM's management team is considered experienced (2.3 years average tenure).

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Grant Bogle
President2.9yrsUS$3.01mNessun dato
H. Horvitz
Co-Founder & Chairman of the Scientific Advisory Boardno dataNessun datoNessun dato
Yi Zhang
Scientific Co-Founder & Member of The Scientific Advisory Boardno dataNessun datoNessun dato
George Daley
Member of the Scientific Advisory Boardno dataNessun datoNessun dato
David Mott
Independent Chairman12.7yrsUS$370.00k0.19%
$ 474.0k
Carl Goldfischer
Independent Director12.9yrsUS$350.00k0.0030%
$ 7.4k
Christopher Walsh
Member of the Scientific Advisory Boardno dataNessun datoNessun dato
Kenneth Bate
Independent Director7.7yrsUS$330.94k0%
$ 0
Bruce Chabner
Member of the Scientific Advisory Boardno dataNessun datoNessun dato
Ronald Evans
Member of the Scientific Advisory Boardno dataNessun datoNessun dato
Joel Huff
Member of the Scientific Advisory Boardno dataNessun datoNessun dato
Steven Henikoff
Member of the Scientific Advisory Boardno dataNessun datoNessun dato

10.2yrs

Durata media

68yo

Età media

Consiglio di amministrazione esperto: EPZM's board of directors are seasoned and experienced ( 10.2 years average tenure).